HomeNewsOpinionJHS Svendgaard: Benefitting from Patanjali 'oral care', capacity ramp-up

JHS Svendgaard: Benefitting from Patanjali 'oral care', capacity ramp-up

The company’s capacity expansion updates and, in particular, its near-term sales guidance make us positive about the stock.

September 04, 2017 / 14:05 IST
Story continues below Advertisement
Patanjali (Image: Facebook)
Patanjali (Image: Facebook)

Anubhav Sahu Moneycontrol Research

Earlier this week, JHS Svendgaard, the contract oral care manufacturer for Patanjali & Dabur, released its Q1 FY18 results. While the quarterly numbers highlighted solid topline growth, it also included one-time settlement income (Rs 27.3 crore) from its earlier customer – P&G – after a prolonged arbitration.

The company’s capacity expansion updates and, in particular, its near-term sales guidance make us positive about the stock.

Story continues below Advertisement

Q1 FY18: guided by improved volume offtake